2018
2022
2019 - 2022
Investments in public and private advanced therapies companies, specialising in biotech investments. Contact: owen@4biocapital.com or op_smith@icloud.com
2018 - 2019
2023
2023
2020
2020
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.
2019
2019
2018 - 2024
2018 - 2024
2017 - 2017
2017 - 2017
LogicBio Therapeutics is a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases. The company’s GeneRide technology hitches a therapeutic transgene to a native promoter without disrupting its normal function in the host genome, enabling permanent expression of a functional version of a missing or faulty gene. Thus − with just a single treatment early in a child’s life – LogicBio can potentially deliver a life-long cure for a devastating disease.
2016 - 2017
2016 - 2017
Depixus is developing unique technology to sequence epigenetic modifications to native RNA and DNA at single molecule level.
2016 - 2017
2016 - 2017
Investment firm focused on early, mid, and late-stage biotech and pharma companies (private and public). Investments involved with: Autolus, Depixus, Verona, OptiKira, LogicBio, Atox Bio
2015 - 2016
2015 - 2016
Investments worked on: Cequr, Apitope, Reneuron
2010 - 2015
2013 - 2015
2010 - 2013